204 related articles for article (PubMed ID: 36862190)
1. Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson's disease: the APOKADO study.
Zagnoli F; Leblanc A; Viakhireva-Dovganyuk I; Delabrousse-Mayoux JP; Pouyet A; Ziegler M; Sogni L; Patat M; Bouillot R; Vérin M;
J Neural Transm (Vienna); 2023 Nov; 130(11):1463-1474. PubMed ID: 36862190
[TBL] [Abstract][Full Text] [Related]
2. Early factors for predicting discontinuation to subcutaneous Apomorphine infusion in Parkinson's disease: A prospective analysis of the Thai Apomorphine Registry.
Phokaewvarangkul O; Anan C; Phimpha A; Chaudhuri KR; van Laar T; Bhidayasiri R
Parkinsonism Relat Disord; 2021 Oct; 91():146-151. PubMed ID: 34624769
[TBL] [Abstract][Full Text] [Related]
3. Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study.
Drapier S; Eusebio A; Degos B; Vérin M; Durif F; Azulay JP; Viallet F; Rouaud T; Moreau C; Defebvre L; Fraix V; Tranchant C; Andre K; Courbon CB; Roze E; Devos D
J Neurol; 2016 Jun; 263(6):1111-9. PubMed ID: 27060084
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
Walter E; Odin P
J Med Econ; 2015 Feb; 18(2):155-65. PubMed ID: 25348011
[TBL] [Abstract][Full Text] [Related]
5. Terminal Care in Parkinson's Disease: Real-Life Use of Continuous Subcutaneous Apomorphine Infusion to Improve Patient Comfort.
Béreau M; Giffard M; Clairet AL; Degenne G; Tatu L; Richfield E; Magnin E; Vérin M; Auffret M
J Parkinsons Dis; 2024; 14(1):209-219. PubMed ID: 38217611
[TBL] [Abstract][Full Text] [Related]
6. EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease.
Dafsari HS; Martinez-Martin P; Rizos A; Trost M; Dos Santos Ghilardi MG; Reddy P; Sauerbier A; Petry-Schmelzer JN; Kramberger M; Borgemeester RWK; Barbe MT; Ashkan K; Silverdale M; Evans J; Odin P; Fonoff ET; Fink GR; Henriksen T; Ebersbach G; Pirtošek Z; Visser-Vandewalle V; Antonini A; Timmermann L; Ray Chaudhuri K;
Mov Disord; 2019 Mar; 34(3):353-365. PubMed ID: 30719763
[TBL] [Abstract][Full Text] [Related]
7. Effects of continuous subcutaneous apomorphine infusion in Parkinson's disease without cognitive impairment on motor, cognitive, psychiatric symptoms and quality of life.
Houvenaghel JF; Drapier S; Duprez J; Robert GH; Riou A; Drapier D; Sauleau P; Vérin M
J Neurol Sci; 2018 Dec; 395():113-118. PubMed ID: 30312901
[TBL] [Abstract][Full Text] [Related]
8. Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review.
Kukkle PL; Garg D; Merello M
Mov Disord Clin Pract; 2023 Sep; 10(9):1253-1267. PubMed ID: 37772305
[TBL] [Abstract][Full Text] [Related]
9. Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study.
Tessitore A; Marano P; Modugno N; Pontieri FE; Tambasco N; Canesi M; Latorre A; Lopiano L; Sensi M; Quatrale R; Solla P; Defazio G; Melzi G; Costanzo AM; Gualberti G; di Luzio Paparatti U; Antonini A
J Neurol; 2018 May; 265(5):1124-1137. PubMed ID: 29516169
[TBL] [Abstract][Full Text] [Related]
10. Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.
Olivola E; Fasano A; Varanese S; Lena F; Santilli M; Femiano C; Centonze D; Modugno N
Neurol Sci; 2019 Sep; 40(9):1917-1923. PubMed ID: 31111272
[TBL] [Abstract][Full Text] [Related]
11. The role of subcutaneous infusion of apomorphine in Parkinson's disease.
Wenzel K; Homann CN; Fabbrini G; Colosimo C
Expert Rev Neurother; 2014 Jul; 14(7):833-43. PubMed ID: 24917215
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study.
García Ruiz PJ; Sesar Ignacio A; Ares Pensado B; Castro García A; Alonso Frech F; Alvarez López M; Arbelo González J; Baiges Octavio J; Burguera Hernández JA; Calopa Garriga M; Campos Blanco D; Castaño García B; Carballo Cordero M; Chacón Peña J; Espino Ibáñez A; Gorospe Onisalde A; Giménez-Roldán S; Granés Ibáñez P; Hernández Vara J; Ibáñez Alonso R; Jiménez Jiménez FJ; Krupinski J; Kulisevsky Bojarsky J; Legarda Ramírez I; Lezcano García E; Martínez-Castrillo JC; Mateo González D; Miquel Rodríguez F; Mir P; Muñoz Fargas E; Obeso Inchausti J; Olivares Romero J; Olivé Plana J; Otermin Vallejo P; Pascual Sedano B; Pérez de Colosía Rama V; Pérez López-Fraile I; Planas Comes A; Puente Periz V; Rodríguez Oroz MC; Sevillano García D; Solís Pérez P; Suárez Muñoz J; Vaamonde Gamo J; Valero Merino C; Valldeoriola Serra F; Velázquez Pérez JM; Yáñez Baña R; Zamarbide Capdepon I
Mov Disord; 2008 Jun; 23(8):1130-6. PubMed ID: 18442107
[TBL] [Abstract][Full Text] [Related]
14. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.
Martinez-Martin P; Reddy P; Katzenschlager R; Antonini A; Todorova A; Odin P; Henriksen T; Martin A; Calandrella D; Rizos A; Bryndum N; Glad A; Dafsari HS; Timmermann L; Ebersbach G; Kramberger MG; Samuel M; Wenzel K; Tomantschger V; Storch A; Reichmann H; Pirtosek Z; Trost M; Svenningsson P; Palhagen S; Volkmann J; Chaudhuri KR
Mov Disord; 2015 Apr; 30(4):510-6. PubMed ID: 25382161
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review.
Smilowska K; van Wamelen DJ; Pietrzykowski T; Calvano A; Rodriguez-Blazquez C; Martinez-Martin P; Odin P; Chaudhuri KR
J Parkinsons Dis; 2021; 11(2):475-489. PubMed ID: 33386813
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Persistence and Monotherapy with Device-Aided Therapies: A Retrospective Analysis of an Israeli Cohort of Patients with Advanced Parkinson's Disease.
Thaler A; Barer Y; Gross R; Cohen R; Bergmann L; Jalundhwala YJ; Giladi N; Chodick G; Shalev V; Gurevich T
Adv Ther; 2022 May; 39(5):2009-2024. PubMed ID: 35247187
[TBL] [Abstract][Full Text] [Related]
17. Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson's Disease: An Open-Label, Randomized, Crossover Study.
Stocchi F; Rascol O; Poewe W; Chaudhuri KR; Kassubek J; Lopez Manzanares L; Zhang Y; Bowling A; Pappert E; Wu S;
J Parkinsons Dis; 2023; 13(8):1329-1342. PubMed ID: 37980683
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson's Disease: A Systematic Review and Bayesian Network Meta-analysis.
Antonini A; Pahwa R; Odin P; Isaacson SH; Merola A; Wang L; Kandukuri PL; Alobaidi A; Yan CH; Bao Y; Zadikoff C; Parra JC; Bergmann L; Chaudhuri KR
CNS Drugs; 2022 Dec; 36(12):1269-1283. PubMed ID: 36414908
[TBL] [Abstract][Full Text] [Related]
19. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
[TBL] [Abstract][Full Text] [Related]
20. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
Wei Q; Tan Y; Xu P; Tao E; Lu Z; Pan X; Wang B; Liu C; Dong X; Tian Y; Sun X; Cattaneo C; Chen S; Shang H;
CNS Drugs; 2022 Nov; 36(11):1217-1227. PubMed ID: 36346534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
